Royalty Pharma plc (RPRX) Revenue by Segment
Royalty Pharma revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Royalty Pharma's largest product or service was Financial Royalty Assets, with $638.03 million or 95% of revenue, up 15.9% from a year earlier. Next: Royalty Income, Other (5%).
The fastest-growing product or service from a year earlier was Royalty Income, Other (+27.9%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q2 fiscal 2019.
Royalty Pharma plc
RPRX
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Royalty Pharma revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Financial Royalty Assets | $638.0M | $595.0M | $578.8M | $550.4M | 95% |
| Royalty Income, Other | $36.1M | $35.6M | $30.5M | $28.2M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Royalty Pharma?
Financial Royalty Assets: $638.03 million, or 95% of revenue, in Q2 fiscal 2026.
What are Royalty Pharma's main products and services?
By revenue in Q2 fiscal 2026: Financial Royalty Assets (95%) and Royalty Income, Other (5%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
